The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into peripheral blood during collection for subsequent autologous transplantation in individuals with multiple myeloma.
Motixafortide (Aphexda, BioLineRx) — administered by subcutaneous injection — is a high-affinity CXCR4 antagonist with a long receptor occupancy of more than 72 hours.
The agent is indicated in combination with the granulocyte colony-stimulating factor filgrastim (Neupogen, Amgen).
Motixafortide blocks CXCR4 on hematopoietic stem cells from binding to its ligand
